For individuals who discover brain lesions on an MRI despite having no neurological symptoms, the period of waiting for a clinical diagnosis can be fraught with uncertainty. This condition, known as radiologically isolated syndrome (RIS), represents a critical window where the brain shows signs of inflammation, but the patient remains asymptomatic. Fresh research suggests that a specific type of lesion may act as a powerful predictor for who will eventually transition from this silent stage to clinical multiple sclerosis (MS).
An international prospective cohort study has found that paramagnetic rim lesions voorspellen klinische MS bij RIS—meaning these specific markers are strongly associated with a higher risk of developing the disease. By identifying these “rim lesions” through advanced imaging, clinicians may be able to pinpoint high-risk patients much earlier than previously possible, potentially opening the door for earlier therapeutic intervention.
The study, published in JAMA Neurology, tracked 79 adults with RIS across three major academic centers between 2011 and 2024. Using 3-Tesla MRI scans of the brain and spinal cord, researchers monitored the presence of white matter lesions, central vein signs, and specifically, paramagnetic rim lesions (PRLs). These PRLs are characterized by a ring of iron-laden macrophages around the lesion, which often indicates a state of chronic, smoldering inflammation.
The Role of Paramagnetic Rim Lesions in Early Detection
In the context of multiple sclerosis, not all lesions are created equal. Whereas standard MRI scans detect areas of demyelination, PRLs represent a more aggressive form of pathology. In patients with RIS, the presence of these rims suggests that the inflammatory process is not just an isolated event but a persistent one, increasing the likelihood that the patient will eventually experience a clinical relapse or a steady decline in neurological function.
The research was structured in two phases to ensure the findings were robust. First, a “discovery cohort” of 36 patients from St. Michael’s Hospital in Toronto, Canada, was analyzed to establish the initial association between PRLs and the onset of MS. Following this, a “validation cohort” of 43 patients from the National Institutes of Health Clinical Center in Bethesda, U.S., and the Fleni MS Clinic in Buenos Aires, Argentina, was used to confirm if the same patterns held true across different populations.
The results were striking. In the discovery group, 25% of participants developed clinical MS, while 21% of the validation group did the same. More importantly, the data revealed that the quantity and presence of PRLs were directly tied to the speed and probability of the disease’s progression.
| Cohort | Key Predictor | Risk Association (OR/HR) |
|---|---|---|
| Discovery (Toronto) | $ge$ 4 PRLs | OR 14.64 |
| Validation (US/Argentina) | Presence of any PRL | OR 20.90 |
| General Trend | Higher PRL count | Increased Hazard Ratio (HR) |
Quantifying the Risk: From Imaging to Diagnosis
The statistical significance of these findings highlights a sharp divide between patients with “stable” RIS and those on a trajectory toward clinical MS. In the discovery cohort, those with four or more paramagnetic rim lesions faced a substantially higher risk of developing the disease, with an odds ratio (OR) of 14.64. In the validation cohort, the mere presence of PRLs was associated with an OR of 20.90, suggesting that even a few of these lesions are highly indicative of future clinical symptoms.
Beyond the probability of developing MS, the study found that a higher number of PRLs was associated with an earlier onset of symptoms. This was evidenced by the hazard ratios (HR) in both groups: 1.15 in the discovery cohort and 1.51 in the validation cohort. Essentially, the more “rimmed” lesions a patient has at the RIS stage, the shorter the window is before they typically experience their first clinical event.
This discovery shifts the conversation around “asymptomatic MS.” Currently, the diagnostic criteria for multiple sclerosis generally require the presence of clinical symptoms (such as vision loss or numbness) in addition to MRI evidence. But, if specific imaging markers like PRLs can accurately predict the disease, there is a growing argument for including asymptomatic patients in diagnostic and treatment frameworks to prevent permanent neurological damage before it occurs.
Who is affected and what it means for patients
The primary group affected by these findings are individuals who undergo “incidental” MRIs—scans ordered for unrelated reasons, such as chronic headaches or concussions—only to uncover white matter lesions. For these patients, the diagnosis of RIS often leads to a “watch and wait” approach. This study suggests that a more nuanced analysis of those lesions, specifically looking for the paramagnetic rim, could provide a clearer prognosis.
The implications for patient care are twofold:
- Risk Stratification: Clinicians can now better distinguish between “low-risk” RIS (few or no PRLs) and “high-risk” RIS (multiple PRLs), allowing for more personalized monitoring schedules.
- Early Intervention: Identifying high-risk individuals may justify the leverage of disease-modifying therapies (DMTs) earlier in the disease course, potentially preserving brain volume and cognitive function.
The Path Toward New Diagnostic Standards
While the study provides a strong signal, it too highlights the complexities of early MS detection. The researchers also tracked “central vein signs” (CVS+L), another marker used to differentiate MS from other mimics like small vessel disease or migraine-related lesions. The synergy between PRLs and these other markers is helping neurologists build a more comprehensive “imaging signature” for the disease.
The broader medical community is currently debating whether the threshold for treating MS should be lowered. If the goal is to prevent the accumulation of disability, waiting for a clinical attack may be too late. The evidence that paramagnetic rim lesions voorspellen klinische MS bij RIS supports the movement toward a “pre-clinical” treatment model, where the target is the lesion rather than the symptom.
As imaging technology evolves, the use of 7-Tesla MRI—which provides even higher resolution than the 3-Tesla machines used in this study—may further refine the detection of these rims, allowing for even more precise risk assessment.
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Patients should consult with a board-certified neurologist or healthcare provider for diagnosis and treatment options regarding multiple sclerosis or radiologically isolated syndrome.
The next step for the clinical community involves integrating these imaging biomarkers into larger, multi-center longitudinal trials to determine if early treatment of RIS patients with PRLs actually improves long-term outcomes compared to the traditional “watch and wait” approach. Further updates on diagnostic criteria changes are expected as the International Panel on MS continues to review emerging evidence.
Do you or a loved one have experience with an RIS diagnosis? We invite you to share your thoughts and questions in the comments below.
